Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ertugliflozin - Merck/Pfizer

Drug Profile

Ertugliflozin - Merck/Pfizer

Alternative Names: MK-8835; PF-04971729; PF-4971729; STEGLATRO

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Merck & Co; Pfizer
  • Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Hypertension

Most Recent Events

  • 30 Apr 2023 Merck and Seoul National University Bundang Hospital completes the phase III ERTU-GLS trial in Type-2 diabetes mellitus (Adjunctive treatment, In adults, In the elderly) in South Korea (NCT03717194)
  • 03 Jun 2022 Efficacy data from the phase III VERTIS CV trial in Type 2 diabetes mellitus presented at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA-2022)
  • 15 Nov 2021 Efficacy data from the phase III VERTIS CV trial in Type 2 diabetes mellitus presented at the American Heart Association Scientific Sessions 2021 (AHA-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top